Contraindicated. Coadministration of doravirine with a solid CYP3A inducer may perhaps decrease doravirine plasma concentrations and/or effects. Probable for lack of virologic reaction and possible resistance to doravirine.pentobarbital will lessen the level or influence of repaglinide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use W